Candel Therapeutics, Inc.
CADL
$5.71
-$0.24-4.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 76.23% | -6.19% | |||
| Gross Profit | -76.23% | 6.19% | |||
| SG&A Expenses | 2.12% | 30.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.48% | 9.86% | |||
| Operating Income | -37.48% | -9.86% | |||
| Income Before Tax | -165.00% | 152.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -165.00% | 152.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -165.00% | 152.43% | |||
| EBIT | -37.48% | -9.86% | |||
| EBITDA | -38.68% | -10.20% | |||
| EPS Basic | -163.68% | 136.95% | |||
| Normalized Basic EPS | -163.68% | 139.01% | |||
| EPS Diluted | -171.62% | 132.85% | |||
| Normalized Diluted EPS | -169.12% | 135.94% | |||
| Average Basic Shares Outstanding | 2.00% | 41.95% | |||
| Average Diluted Shares Outstanding | -5.98% | 53.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||